HomeBlogDoes the IV Route Change What NAD+ Actually Does? What the 2026 Research Found for Oklahoma City Patients

If you have looked into NAD+ at all, you have probably read two kinds of page. One says NAD+ falls with age and that restoring it supports cellular energy. The other says the human trials are underwhelming. Both pages are usually describing the same thing: a capsule. What an Oklahoma City clinic is actually offering you is an infusion, and the reasonable question — does the route change the answer? — has had almost no pooled randomized evidence behind it, because until this month no meta-analysis had included an intravenous arm at all. One now has.

Almost every NAD+ trial you have read about used a capsule

The largest recent synthesis of NAD+ precursors and fatigue, a network meta-analysis published in Frontiers in Nutrition in September 2026, pooled 27 studies and 1,599 adults taking nicotinamide riboside, nicotinamide mononucleotide, NADH or nicotinamide. Its headline result is worth sitting with: no precursor significantly improved perceived fatigue or sleep quality. Nicotinamide mononucleotide did improve endurance in a dose-dependent way (medium dose SMD 0.66, 95% CI 0.09 to 1.23; high dose SMD 1.02, 95% CI 0.43 to 1.60), while neuromuscular strength did not change. We have written about that split in more detail here. The point for today is narrower: that entire body of evidence describes oral precursors, not an intravenous infusion of NAD+ itself.

The first pooled analysis to include intravenous NAD+ — and what it was studying

On 17 November 2026, European Journal of Clinical Pharmacology published a systematic review and meta-analysis of NAD+ and its precursors that, for the first time, included trials in which the intervention was given by vein. The authors searched five databases from inception to September 2025 and pooled four randomized controlled trials covering 387 patients. The interventions were intravenous NAD+ or oral nicotinamide riboside against placebo.

The population matters more than the route here, and it is the first thing to be clear about. Every patient in those trials was an adult with symptomatic heart failure already receiving guideline-directed cardiac therapy. This is a cardiology question asked of cardiology patients. Venturis Clinic does not treat heart failure, and nothing in this paper was measured in healthy adults who feel tired. It is still the best available look at what an intravenous NAD+ infusion has and has not been shown to do in a randomized setting.

What it found, and the one number that did move

On the outcomes the authors set out to measure, the pooled result was consistently non-significant. Heart failure hospitalization did not fall significantly (3 studies, 268 patients; RR 0.63, 95% CI 0.36 to 1.09). Neither did all-cause mortality (2 studies, 238 patients; RR 0.51, 95% CI 0.09 to 2.86). Left ventricular ejection fraction did not differ significantly at one month (MD 2.10%, 95% CI −0.18 to 4.38), at three months (MD −0.48%, 95% CI −4.74 to 3.78), or at last follow-up (MD 1.54%, 95% CI −0.69 to 3.77). NT-proBNP, a blood marker of cardiac strain, did not differ significantly either (MD −382.76 pg/mL, 95% CI −1091.62 to 326.11).

One measure did change. Serum creatinine, a routine marker of kidney function, rose significantly in the NAD+ groups (2 studies, 209 patients; MD 7.46 micromoles per liter, 95% CI 2.21 to 12.71, P = 0.005), while liver enzymes did not differ. The authors describe the interventions as generally well tolerated in the short term and say plainly that the creatinine finding warrants further evaluation and that larger, longer randomized trials are needed.

When two routes were compared head to head, the route changed the breakdown products

The closest thing to a human route comparison came earlier in 2026, in a Scientific Reports crossover trial published in June. Fourteen healthy adult men took a single dose of nicotinamide mononucleotide sublingually and orally, in random order, separated by an eight-day washout, with blood sampled over 60 minutes. The sublingual route produced a significantly higher incremental area under the curve for the terminal breakdown products 2PY and 4PY. It did not produce a significant difference in blood concentrations of nicotinamide mononucleotide, nicotinamide, or NAD+ itself. Both routes were well tolerated with no adverse events reported.

Two caveats belong with that. Sublingual is not intravenous, so this is an analogy rather than a test of the drip. And the study was conducted by researchers at a commercial food and nutrition company, which is worth knowing when reading any supplement pharmacokinetic paper. Even so, the pattern is instructive: changing the route visibly changed the metabolite curve and did not change the measure most people assume a better route buys them.

When three boosters were compared head to head, the gut turned out to be part of the mechanism

A randomized, placebo-controlled trial in Nature Metabolism, published in January 2026, gave 65 healthy participants 14 days of nicotinamide riboside, nicotinamide mononucleotide or nicotinamide. The two popular precursors raised circulating NAD+ comparably; nicotinamide did not. Then the authors did something more revealing. Testing the compounds directly in whole blood outside the body, they found that nicotinic acid was a potent NAD+ booster while nicotinamide riboside, nicotinamide mononucleotide and nicotinamide were not, and that the first two give rise to nicotinic acid through human gut microbiota. They propose a gut-dependent model for how the popular precursors work at all.

The authors are based at a large commercial nutrition company, which again is context rather than a disqualification. The implication is the interesting part: if a meaningful share of an oral precursor’s effect runs through the gut, then an infusion bypasses that step. Whether bypassing it helps, hurts, or makes no difference has not been tested in people.

What these papers add up to

Route and compound demonstrably change the pharmacology in ways you can measure in blood. Not one of these papers shows that changing the route changes how a person feels. The fair summary is that intravenous NAD+ is better studied than it was a month ago, that what was studied was cardiac outcomes in heart failure rather than energy in healthy adults, and that the only measure that moved in the pooled analysis was a kidney marker. NAD+ IV Therapy for Energy Restoration is a service we offer and talk about openly, including its limits.

Who is generally not a good candidate for an NAD+ infusion

Saying who should not do something is more useful than another list of benefits. In our experience the following are reasons to slow down or decline:

  • Anyone who has not had basic bloodwork, including kidney function. The creatinine signal above is exactly why a current metabolic panel comes before a first infusion, not after it.
  • Anyone with reduced kidney function or active kidney disease, until the physician managing that condition has weighed in. This is not a decision to make in an infusion chair.
  • Anyone with heart failure hoping this is cardiac treatment. The pooled trials did not show significant improvement in hospitalization, mortality or ejection fraction, and heart failure care belongs with a cardiologist.
  • Anyone who is pregnant or breastfeeding, where there is no meaningful safety evidence for these infusions.
  • Anyone whose main complaint is unexplained fatigue who has not had the ordinary causes looked at — iron status, thyroid function and B12 among them. We have written about the iron test that often gets skipped, and that evaluation is cheaper and more informative than any infusion.

Four questions worth asking before any NAD+ infusion

  1. What bloodwork do you want before my first infusion, and does it include kidney function?
  2. What exactly is in the bag, at what dose, and over how long?
  3. What outcome are we going to measure, and at what point would we agree this did not work?
  4. What in my history would make you tell me no?

Any clinic should be able to answer all four before taking payment.

Frequently asked questions

Is intravenous NAD+ FDA-approved?

No. NAD+ infusions are not FDA-approved for treating fatigue, aging, cognitive complaints or any of the uses they are commonly marketed for. They are administered as an off-label wellness intervention, which is a reason to ask more questions, not fewer.

Is there randomized evidence for intravenous NAD+?

A little, and it arrived in November 2026. A meta-analysis in European Journal of Clinical Pharmacology pooled four randomized trials and 387 patients in which the intervention was intravenous NAD+ or oral nicotinamide riboside. Those patients all had symptomatic heart failure, not ordinary fatigue.

Does an IV absorb better than a capsule?

An infusion bypasses digestion, which is real. Whether that produces a better result is a different question, and the published human route comparisons have not shown it yet. A June 2026 crossover trial found a sublingual route changed breakdown-product levels without changing measured NAD+.

Is NAD+ infusion safe for the kidneys?

The November 2026 pooled analysis found a small but statistically significant rise in serum creatinine in the NAD+ groups, and its authors say this warrants further evaluation. That is a reason to check kidney function before starting and to discuss any existing kidney condition with your own physician.

Will an NAD+ infusion fix my fatigue?

Nobody can tell you that, and the research does not support promising it. The largest fatigue synthesis found no NAD+ precursor significantly improved perceived fatigue, while endurance measures did improve. Patients may experience different things, and results vary. The honest step is to measure first.

What is the difference between NAD+, NMN and nicotinamide riboside?

NAD+ is the coenzyme itself. Nicotinamide mononucleotide and nicotinamide riboside are precursors the body converts into it, usually taken by mouth. A January 2026 trial found both precursors raised circulating NAD+ while plain nicotinamide did not, and suggested gut bacteria play a part in how they do it.

Talk it through in Oklahoma City

If you are considering an NAD+ infusion, or you have already had a course of them and want to understand what did and did not change, that is a conversation worth having with your labs on the table. Our Vitamin Infusion Therapy and NAD+ services are part of a broader functional and regenerative practice, and candidates are typically evaluated for suitability during a consultation rather than at a menu board.

Venturis Clinic
7917 N May Ave, Suite B, Oklahoma City, OK 73120
Phone: (405) 848-7246
Serving Oklahoma City, Edmond, Moore, Norman, Yukon, Mustang, Piedmont, Nichols Hills, Bethany and Warr Acres.

This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.

Sources

  1. Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. Impact of exogenous nicotinamide adenine dinucleotide and its precursors supplementation in adults with heart failure: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. 2026;82(12). DOI: 10.1007/s00228-026-04202-8
  2. Gao Y, Li S, Guan J, et al. Domain-specific effects of NAD+ precursors on fatigue and functional performance: a systematic review and network meta-analysis. Frontiers in Nutrition. 2026;13:1890335. DOI: 10.3389/fnut.2026.1890335
  3. Wakabayashi J, Higashi S, Morifuji M. Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men. Scientific Reports. 2026;16(1). DOI: 10.1038/s41598-026-57552-9
  4. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8(1):62–73. DOI: 10.1038/s42255-025-01421-8

Article records located through PubMed. Figures above were read directly from the published abstracts of the papers cited.

Wondering if this applies to you?

Every patient is different. Request a free 15-minute discovery call and our team will listen to what you have been dealing with and help you decide on a next step.

Request a free 15-minute discovery callor call (405) 848-7246

author avatar
Venturis Clinic